Eagle Bio’s 25(OH) Vitamind D ELISA Assay Kit was used in a recent study. The Vitamin D 25(OH) ELISA is a quick, simple, and sensitive assay for the quantitative determination of Vitamin D in human serum and plasma. This assay is a part of our Bone Metabolism Assay Kit line, an assay line that offers a comprehensive product group for analyzing  the concentration of a variety of samples in serum, plasma, tissue,saliva, and urine.

Publication Citing Eagle Bio’s 25(OH) Vitamind D ELISA:

Common Variants rs11191548 near the CYP17A1 Gene is associated with Hypertension and the Serum 25(OH) D levels in Han Chinese

Zhang, Ning et al. (2018). Common Variants rs11191548 near the CYP17A1 Gene is associated with Hypertension and the Serum 25(OH) D levels in Han Chinese. Journal of Human Genetics. 63:731-737.

Summary:

This study investigated the relationship between hypertension and serum 25(OH) Vitamin D levels in Han Chinese in association with genetic varints in the CYP17A1 gene. It was determined that the rs11191548 mutation in the CYP17A1 gene is associated with higher 25(OH) Vitamin D levels in those with hypertension. 

Eagle announces the introduction of an Intact MMAF ADC ELISA Assay Kit to its line of existing Antibody Drug Kits. This Intact MMAE Kit is the first of its kind, allowing for the measurement of conjugated antibody in a variety of sample types.

What is MMAF (Monomethyl auristatin F)?

MMAF is a new type of targeted therapy for cancer treatment. It is a synthetic antineoplastic agent that is a toxic compound; when linked to a monoclonal antibody (mAb) it gets directed to cancer cells. This drug treatment targets tumors and inhibits their growth by blocking the polymerization of tubulin in the cell. Measuring circulating specific ADC’s is importatnt for pre-clinical and clinical studies for the discovery of unique, targeted, safer, effective cancer treatments.

Key Advantages to Eagle Biosciences’s Antibody Drug Conjugates Assays:

  • Excellent Sensitity
  • Simple Procedure
  • Wide Dynamic Range
  • Quick Results: Under 3 hours
  • Versatile: multiple sample types and species

Related Kits:

MMAF Antibody Drug Conjugate (ADC) ELISA Assay Kit

MMAE Antibody Drug Conjugate (ADC) ELISA Assay Kit

Intact MMAE ADC ELISA Assay Kit

image by the Guardian

A ground breaking gene therapy has the potential to help
mend damaged nerves in the spin and help those paralyzed by spinal cord
injuries. This new therapy works by utilizing an enzyme called chondroitinase.
This enzyme has the ability to break down scar tissue and by doing so allows
severed nerves to connect again.

Rats treated with this therapy for a period of time were
able to relearn some basic skill such as grabbing with their limbs. The therapy
can treat large areas of the spinal cord at once, and the hope is that one day
the treatment will be able to help people with spinal cord injuries regain the
ability to perform some daily tasks such as using utensils, picking up things,
and writing.

Though this therapy is a breakthrough in regenerative
medicine there is still some hurdles that need to be cleared before it can be
brought to human trials. The research team needs to prove the treatment can
work effectively in larger mammals before bringing it to human trials. They
also want to find a way to stop the therapy for working once the spine is
healed.  

Read More.

References:

1. Sample Ian. “Paws and play: gene treatment helps rats with
spinal cord injuries regain their nerve.” The Guardian. 14 Jun 2018.  

The Eagle Biosciences DM-1 Antibody Drug Conjugate ELISA Assay Kit was recently used in a study researching targeted cancer therapies. This kit is a part of our line of Cancer Biomarker Kits. These cancer biomarker kits are highly sensitive and specific assays tests for quantifying of specific biomarkers in various sample types for university, pharmaceutical, or clinical research.

Levels of DM-1 conjugate (Trastuzumab emtansine) were determined usign Eagle Biosciences DM-1 Antibody Drug Conjugate ELISA Assay Kit. 

Read More.

Reference:

[1]. Verkade, J.M.M.; WiJdeven, M.A.; van Geel, R.; Janssen, B.M.G.; van Berkel, S.S.; van Delft, F.L. A Polar Sulfamide Spacer Significantly Enhances the Manufacturability, Stability, and Therapeutic Index of Antibody-Drug Conjugates. Antibodies 2018 7:12.

image by Bru-nO pixaby

A women with late stage breast cancer, given less than five years to live, participates in an experimental T-cell immunotherapy. After several rounds of failed chemotherapy, this experimental trial used the women’s own immune cells to target and fight off the tumor, leaving her cancer free for two years. 

This new therapy, though still experimental and expensive, shows a promising outlook for helping other patients with metastatic breast cancer, and other cancers such as prostate and ovarian cancer.

Read More. 

[1]. Sample, Ian, and Jessica Glenza. “Doctors Hail World First as Woman’s Advanced Breast Cancer Is Eradicated.” The Guardian, Guardian News and Media, 4 June 2018.

Eagle announces the introduction of an Intact MMAE ADC ELISA Assay Kit to its line of existing Antibody Drug Kits. This Intact MMAE Kit is the first of its kind, allowing for the measurement of conjugated antibody in a variety of sample types. 

What is MMAE (Monomethyl auristatin E)?

MMAE is a new type of targeted therapy for cancer treatment. It is a synthetic antineoplastic agent that is a toxic compound; when linked to a monoclonal antibody (mAb) it gets directed to cancer cells. This drug treatment targets tumors and inhibits their growth by blocking the polymerization of tubulin in the cell. Measuring circulating specific ADC’s is importatnt for pre-clinical and clinical studies for the discovery of unique, targeted, safer, effective cancer treatments.

Key Advantages to Eagle Biosciences’s Antibody Drug Conjugates Assays:

  • Excellent Sensitity
  • Simple Procedure
  • Wide Dynamic Range
  • Quick Results: Under 3 hours
  • Versatile: multiple sample types and species

Related Kits:

MMAE Antibody Drug Conjugate (ADC) ELISA Assay Kit

Now Available: Human Anti-IgE Antibody ELISA!

Human Anti-IgE Antibody ELISA Assay Kit

This Eagle Biosciences Human Anti-IgE Antibody ELISA Assay Kit is produced for the quantitative determination of human anti-human IgE antibody levels in human serum or plasma samples. The test may be useful for detecting patients who have developed antibodies (mainly IgG) to their own IgE. This kit is for research purposes only. It is not for use in diagnostic procedures.

Size: 1×96 wells
Sensitivity: 0.4808 ng/mL
Dynamic Range: 12 – 450 ng/mL
Incubation Time: >3 hours
Sample Type: Serum or Plasma
Sample Size: 0.2 mL

SHORT ASSAY PROTOCOL

  1. Add 100 μL of calibrators, control and patient sample to the plate
  2. Incubate 1 hour at RT, shaking
  3. Wash strips with diluted wash buffer
  4. Add 100 μL biotin Antibody
  5. Incubate 30 min at RT, shaking
  6. Wash strips with diluted wash buffer
  7. Add 100 μL Streptavidin-HRP
  8. Incubate 30 min at RT, shaking
  9. Wash strips with diluted wash buffer
  10. Add 100 μL TMB substrate
  11. Incubate 20 min at RT
  12. Add 100 μL stop solution
  13. Read strips at OD 450 nm

Mediagnost along with Eagle Biosciences, Inc. has released an improved test for human Adiponectin in serum and plasma samples*. This Total Adiponectin ELISA Assay Kit has been upgraded with the following features;

  • is extremely sensitive (less than 0.3 ng/ml)
  • is fast: incubation time a total of 1 hour and 45 minutes
  • Single Standards with 2, 10, 30, 70, 100 ng/ml human Adiponectin are provided in the Kit
  • 2 Control Sera are provided for quality control purposes according GLP
  • is calibrated with native Adiponectin
  • uses high affinity monoclonal antibodies against human Adiponectin
  • Microtiter plates are separately breakapart
  • Available for humanmouse and rat samples

For more information click here

Read IFU Here 

*The Adiponectin ELISA is for Research Use Only 

We have been very busy these past few months gathering a bunch of new products to offer our great and loyal customers! Some of these new products have been added to our ever-growing Bone Metabolism Assays


Research on the effects of various cancers and abnormalities in the skeletal system are on the rise and we are excited to start offering more tests! 


Soluble Semaphorin 4D ELISA: 

For the direct determination of soluble Semaphorin 4D in human plasma samples. 

Semaphorin 4D (SEMA4D or CD100) is a member of a family of trans membranes and secreted proteins that regulates key cellular functions and is involved in cell-cell communication. SEMA4D participates in numerous physiological processes such as axon guidance, immune regulation, angiogenesis, tumor progression, and bone metabolism. SEMA4D has emerged to a novel therapeutic target in cancer and in bone diseases. 


Bioactive Sclerostin ELISA: 

For the quantitative determination of bioactive sclerostin in human serum, EDTA plasma, and citrate plasma.


Sclerostin is nearly exclusively produced in osteocytes. Mutations in the Sclerostin (SOST) gene can cause sclerosteosis and van Buchem disease which are bone dysplasia disorders characterized by progressive skeletal overgrowth. Sclerostin levels are altered in response to hormonal stimuli or due to pathophysiological conditions. Sclerostin concentrations are increased in disorders such as hypoparathyroidism, Paget’s disease, multiple myeloma and in cancer induced bone diseases.



OsteomiR (Coming Soon!) 

For the quantification of selected microRNA biomarker candidates for fracture-risk in postmenopausal and diabetic osteoporosis in human serum samples.

MicroRNAs are small non-coding RNAs that regulate gene expression through RNA interference and therefore contribute to the regulation of correct cell and tissue function. MicroRNA secretion (contained in exosomes or microvesicles) has been observed in many different cell types, and is believed to serve as an endocrine pathway for cell-to-cell communication. Therefore, the analysis of circulating microRNAs in serum, urine or saliva can be used to obtain valuable information about tissue physiology and pathophysiology. Circulating microRNAs are a novel class of relevant serum biomarkers.


Keep an eye out for all the other great new products we are releasing in the next few months!


Looking for a specific ELISA? Email us what you’re looking for and we can try to make it happen! 

Eagle Biosciences Vitamin D ELISA Kit has been used once again in breakthrough research! 

Background: Influenza continues to cause significant morbidity and mortality each year. Vaccination is the primary prevention; however, its effectiveness may be limited even among young, healthy adults. Vitamin D deficiency is highly prevalent and may be associated with poor vaccine immunogenicity and an increased risk for respiratory infections.

Methods: We conducted a retrospective cross-sectional study among young, healthy military personnel to evaluate the associations between 25(OH)D levels with post-influenza vaccination antibody titers (seroprotection defined as a titer of ≥1:40 post-vaccination) and healthcare encounters for respiratory infections during the 2009-2010 influenza season. 25(OH)D levels were analyzed as continuous and categorical [normal (>30 ng/ml), insufficient (20-30 ng/ml), and deficient (<20 ng/ml)] variables. Separate univariate and multivariable logistic regression models were utilized to determine the associations between 25(OH)D levels with antibody responses and respiratory conditions adjusting for possible confounders.

Results: A total of 437 subjects were evaluated. Most participants were young adults (91% were 18-39 years of age), 50% were male, and 56% resided in the southern U.S. Overall, 152 (35%) were vitamin D deficient, 167 (38%) insufficient, and 118 (27%) had normal 25(OH)D levels. There were no demographic differences by 25(OH)3 category. Only 224 (51%) demonstrated a seroprotective anti-influenza post-vaccination titer, which did not vary by categorical 25(OH)D levels [vitamin D deficient vs. normal: OR 1.10 (0.68-1.78) and insufficient vs. normal: OR 1.25 (0.78-2.01)] or continuous vitamin D levels [OR 0.98 (0.84-1.15)]. There were no associations with respiratory diagnoses between the vitamin D groups.

Conclusion: Vitamin D insufficiency and deficiency were highly prevalent despite evaluating a young, healthy adult population. There were no significant associations between 25(OH)D levels and post-vaccination antibody titers or respiratory infections. Strategies for improving influenza vaccine responses are needed since only one-half of vaccinees demonstrated seroprotective anti-influenza titers.

ReferenceRachel Lee, MD1, Seunghyun Won, PhD2,3, Christian Hansen, BS1 and Nancy Crum-Cianflone, MD, MPH2,4,5, (1)Operational Infectious Diseases, Naval Health Res. Ctr., San Diego, CA, (2)Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD, (3)Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, (4)Scripps Mercy Hospital, San Diego, CA, (5)Naval Medical Center San Diego, San Diego, CA